1-2 of 2
Bart Barlogie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Frits van Rhee, Susann M. Szmania, Myles Dillon, Anne M. van Abbema, Xin Li, Mary K. Stone, Tarun K. Garg, JuMei Shi, Amberly M. Moreno-Bost, Rui Yun, Balaji Balasa, Bishwa Ganguly, Debra Chao, Audie G. Rice, Fenghuang Zhan, John D. Shaughnessy, Jr., Bart Barlogie, Shmuel Yaccoby, Daniel E.H. Afar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (9): 2616–2624.
https://doi.org/10.1158/1535-7163.MCT-09-0483
Published: 17 September 2009
View article titled, Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Open the PDF for Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma in another window
Includes: Supplementary data
Journal Articles

Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma

Erming Tian, Terry H. Landowski, Owen W. Stephens, Shmuel Yaccoby, Bart Barlogie, John D. Shaughnessy, Jr.
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 500–509.
https://doi.org/10.1158/1535-7163.MCT-07-0524
Published: 17 March 2008
View article titled, Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
Open the PDF for Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma in another window